Codice QR

Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial

BackgroundLocally advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma faces high recurrence risks despite radical surgery. Perioperative chemotherapy (e.g., FLOT regimen) improves survival but has limited pathological complete response (pCR) rates and significant toxicity. Immunotherap...

Descrizione completa

Salvato in:
Autori principali: Xiangyu Meng, Dong Yang, Yuanlin Liu, Chao Wang, Junqiao Yao, Tao Zhang
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2025-07-01
Serie:Frontiers in Immunology
Soggetti:
G/GEJ adenocarcinoma
perioperative treatment
fruquintinib
sintilimab
effectiveness
Accesso online:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1638316/full
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi